Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma.

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 28880268)

Published in Cell Death Dis on September 07, 2017

Authors

Jia-Hong Wang¹^,2, Xiao-Ping Zhong¹, Yong-Fa Zhang³^,4^,5, Xiao-Liang Wu⁶, Shao-Hua Li¹, Pei-En Jian¹, Yi-Hong Ling¹, Ming Shi¹, Min-Shan Chen¹, Wei Wei¹, Rong-Ping Guo¹

Author Affiliations

1: Department of Hepatobilliary Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
2: Department of Abdominal Surgery, Affiliated Cancer Hospital &Institute of Guangzhou Medical University, Guangzhou, Guangdong, China.
3: Department of Liver Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
4: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
5: Department of Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
6: Department of Oncology, Guizhou Provincial People's Hospital, Guiyang, China.

Articles cited by this ↗

Global cancer statistics. CA Cancer J Clin (2011) 185.92

Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer (2002) 34.99

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78

Hepatocellular carcinoma. N Engl J Med (2011) 19.40

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol (2003) 6.14

Loco-regional treatment of hepatocellular carcinoma. Hepatology (2010) 3.59

Molecular mechanisms of hepatocellular carcinoma. Hepatology (2008) 3.51

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst (2005) 2.73

The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology (2013) 2.63

Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery (2000) 2.14

Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist (2006) 2.05

Epithelial mesenchymal interactions in cancer and development. Cell (2001) 1.77

Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res (1999) 1.77

NF-kappaB suppression by the deubiquitinating enzyme Cezanne: a novel negative feedback loop in pro-inflammatory signaling. J Biol Chem (2008) 1.74

NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene (2008) 1.58

A novel type of deubiquitinating enzyme. J Biol Chem (2003) 1.57

Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg (1998) 1.54

Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol (2002) 1.52

Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci (2008) 1.49

Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer (2001) 1.49

Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J Hepatol (2011) 1.30

Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol (2009) 1.29

Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett (2005) 1.26

Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol (2000) 1.24

Wnt/β-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1α signaling. Carcinogenesis (2013) 1.22

Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study. Semin Oncol (1997) 1.19

Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg (2009) 1.16

Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol (2004) 1.01

Prediction of recurrence and extratumor spread of hepatocellular carcinoma following resection. J Surg Oncol (2000) 0.87

Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: a non-randomized comparative study. Hepatogastroenterology (2012) 0.85

Biological and clinical implications of retinoic acid-responsive genes in human hepatocellular carcinoma cells. J Hepatol (2013) 0.81

The effect of postoperative TACE on prognosis of HCC: an update. Hepatogastroenterology (2013) 0.80

Early recurrence after curative resection in oligonodular hepatocellular carcinoma. Hepatogastroenterology (2013) 0.79

Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma. J Transl Med (2015) 0.76

Articles by these authors ⇆

Preoperative Carbohydrate Antigen 19-9: Its Neglected Role in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Patients. J Gastrointest Surg (2017) 0.75